查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1552555

焦虑症和忧郁症治疗市场规模、份额、趋势分析报告：按药物、适应症、分销管道、地区和细分市场预测，2024-2030年

Anxiety Disorders And Depression Treatment Market Size, Share & Trends Analysis Report By Drug (Antidepressants, Anxiolytics, Anticonvulsants, & Others), By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格
简介目录

焦虑症和忧郁症治疗市场的成长和趋势

预计到2030年，全球焦虑忧郁症治疗市场规模将达到158.8亿美元。

2024年至2030年的复合年增长率预计为3.6%。全球忧郁症盛行率上升预计将推动未来几年的市场成长。近年来，由于设备和心理治疗的采用增加，抗忧郁症的需求有所下降。

容易患忧郁症的老年人口不断增加，恐惧症和整体焦虑症等焦虑症的迅速增加，将进一步推动预测期内治疗精神疾病的抗忧郁症的需求不断增长。此外，采用先进技术的治疗方法，例如用于大脑刺激的医疗植入和使用基于智慧型手机的应用程式的虚拟实境暴露疗法，为患者提供了创新的治疗选择。

焦虑症和忧郁症治疗市场报告亮点

  • 目前，抗忧郁症领域占据了最大的收益占有率。然而，由于与这些治疗相关的不利事件发生率不断增加，预计该领域的成长将会下降。
  • 抗忧郁症市场的下滑是由于品牌药专利到期以及采用具有成本效益的生物学名药所致。
  • 同时，Duloxetine、Fezzima 和 Brintellix 等新药的采用预计将在未来几年推动治疗需求。
  • 此外，由于与药品相比副作用较少，医疗保健专业人员越来越多地采用个人化治疗和设备，因此预计个人化治疗和设备领域将实现最快的成长。
  • 由于多种药物的可用性以及该地区忧郁症的高盛行率，北美地区的焦虑和忧郁症治疗已达到饱和水平。
  • 由于学名药在市场上占据主导地位，抗忧郁症的收益预计在预测期内将下降。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章：焦虑症和忧郁症治疗市场变数、趋势和范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 焦虑症和忧郁症治疗市场的变数市场分析工具
    • 波特的分析
    • PESTEL分析

第四章焦虑症和忧郁症治疗市场的变数：药物、估计和趋势分析

  • 细分仪表板
  • 焦虑症与忧郁症治疗市场变数市场：药品波动分析，百万美元，2023 年和 2030 年
  • 抗忧郁症
    • 2018-2030年抗忧郁症市场收益估计与预测
  • 抗焦虑药
    • 2018-2030年抗焦虑药物市场收益估计与预测
  • 抗惊厥药
    • 2018-2030年抗癫痫药物市场收益估计与预测
  • 去甲肾上腺素促效剂
    • 去甲肾上腺素能促效剂市场收益估计与预测，2018-2030
  • 非典型抗精神病药
    • 2018-2030年非典型抗精神病药物市场收益估计与预测

第五章焦虑症与忧郁症治疗市场：适应症、估计与趋势分析

  • 细分仪表板
  • 焦虑症与忧郁症治疗市场：适应症变异分析，百万美元，2023 年和 2030 年
  • 忧郁症
  • 焦虑症

第六章焦虑症与忧郁症治疗市场：通路、估计与趋势分析

  • 细分仪表板
  • 焦虑症和忧郁症治疗市场：分销管道变化分析，百万美元，2023 年和 2030 年
  • 医院
  • 零售药房
  • 网路药房

第七章焦虑症与忧郁症治疗市场：区域估计与趋势分析

  • 2023 年和 2030 年按地区分類的焦虑症和忧郁症治疗市场占有率，百万美元
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
  • 拉丁美洲
    • 巴西
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Pfizers Inc.
    • H. Lundbeck A/S
    • Glaxo SmithKline Pharmaceuticals Ltd.
    • Merck &Co., Inc.
    • Eli Lilly &Company
    • AstraZeneca
    • Bristol-Myers Squibb
    • Johnson &Johnson
    • AbbVie Inc.
    • Sanofi
简介目录
Product Code: GVR-1-68038-731-5

Anxiety Disorders And Depression Treatment Market Growth & Trends:

The global anxiety disorders and depression treatment market is expected to reach a value of USD 15.88 billion by 2030. The market is projected to grow at a CAGR of 3.6% from 2024 to 2030. The rising incidence of depression worldwide is anticipated to drive the market growth in the coming years. Increasing adoption of devices and psychotherapies has resulted in the declining demand for antidepressants in recent years.

The rising geriatric population prone to depression and surging prevalence of anxiety disorders, including phobias and generalized anxiety disorder, are further contributing toward the growing demand for antidepressants to treat mental illnesses over the forecast period. Moreover, the introduction of technologically advanced therapies, such as medical implants used for brain stimulation and virtual reality exposure therapies using smartphone-based applications, furnish patients with innovative treatment alternatives.

Anxiety Disorders And Depression Treatment Market Report Highlights:

  • Presently, the antidepressant drugs segment holds the largest revenue share. However, due to the rising occurrence of adverse events associated with these therapeutics, this segment's growth is expected to wane
  • Patent expiration of branded medicines and the introduction of generic biosimilars, which are cost-effective, are responsible for the shrinking market of antidepressants
  • On the other hand, the introduction of new medicines, such as Duloxetine, Fetzima, and Brintellix, is predicted to fuel the demand for therapeutics in the coming years
  • Furthermore, the personalized therapies and devices segment is expected to register the fastest growth owing to its growing adoption by healthcare professionals as they exert fewer side effects as compared to drugs
  • North American regional segment for anxiety disorders and depression treatment reached a saturation level owing to the availability of several medicines and the high prevalence of depressive disorders in this region
  • The revenue captured by antidepressants is expected to decrease with generics dominating the market during the forecast period

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Anxiety Disorders and Depression Treatment Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Anxiety Disorders and Depression Treatment Market Variables Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Anxiety Disorders and Depression Treatment Market Variables : Drugs Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Anxiety Disorders and Depression Treatment Market Variables Market: Solution Movement Analysis, USD Million, 2023 & 2030
  • 4.3. Antidepressants
    • 4.3.1. Antidepressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.4. Anxiolytics
    • 4.4.1. Anxiolytics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Anticonvulsants
    • 4.5.1. Anticonvulsants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Noradrenergic Agents
    • 4.6.1. Noradrenergic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Atypical Antipsychotics
    • 4.7.1. Atypical Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Anxiety Disorders and Depression Treatment Market : Indication Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Anxiety Disorders and Depression Treatment Market: Technology Movement Analysis, USD Million, 2023 & 2030
  • 5.3. Depression
    • 5.3.1. Depression Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Anxiety
    • 5.4.1. Anxiety Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Anxiety Disorders and Depression Treatment Market : Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Anxiety Disorders and Depression Treatment Market: End-user Movement Analysis, USD Million, 2023 & 2030
  • 6.3. Hospitals
    • 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online Pharmacies
    • 6.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Anxiety Disorders and Depression Treatment Market : Regional Estimates & Trend Analysis

  • 7.1. Anxiety Disorders and Depression Treatment Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Anxiety Disorders and Depression Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Pfizers Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. H. Lundbeck A/S
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Glaxo SmithKline Pharmaceuticals Ltd.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Merck & Co., Inc.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Eli Lilly & Company
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. AstraZeneca
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Bristol-Myers Squibb
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Johnson & Johnson
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. AbbVie Inc.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Sanofi
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives